home Contacts Site Map International site Search Boehringer Ingelheim (Russia) 31 March 2021 news Multimedia library About company Career Drugs Press Contacts news News archive 05/20/2016 Pavol Dobrocki: “Boehringer Ingelheim confirms its commitment to the Russian market” Pavol Dobrotski, CEO of Boehringer Ingelheim, took part in the Russian Pharmaceutical Forum in St. Petersburg, organized by the Adam Smith Institute, and spoke as part of a panel discussion on growth prospects in today's environment. He confirmed the company's commitment to the Russian market and outlined the key development drivers in it in the short and medium term. The Russian Pharmaceutical Forum is the largest industry event. This year, more than 600 attendees discussed key issues and topics that are at the center of attention of leading industry experts. Together with Pavel Dobrotski, heads of R-Pharm, MSD and Janssen took part in the panel discussion “Growth prospects in modern conditions”. “We confirm our commitment to the Russian market and interest in further development in Russia ,” Pavol Dobrotski emphasized in his speech. “The interests of the patient have been and remain a priority for the company, and our drugs are indeed life-saving.” The CEO of Boehringer Ingelheim noted that the company's strategy in the medium and long term will be based on further development through innovation and the creation of partnerships and alliances: by 2020 alone, we intend to invest in these areas at a global level of 11 billion euros. In general, the forum and panel discussions were productive, topics and directions for further work and development were outlined. To the begining Rss Printing © 2021 , LLC "BERINGER INGELHEIM", All rights reserved